Abbvie submits NDA for HCV regimen


The regulatory filing for Abbvie's (ABBV) three-drug regimen for Hepatitis C infection triggers a $20M milestone payment to collaboration partner Enanta Pharmaceuticals (ENTA).

The company developed the protease inhibitor ABT-450 which, in combination with ritonavir, is one leg of the antiviral regimen.

Enanta received $57M from Abbvie when the collaboration was signed and $55M in subsequent milestone payments exclusive of the latest $20M. The firm is eligible to receive up to an additional $175M for regulatory and commercial milestones as well as double digit royalties on global sales.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs